Skip to content
OpenCapital
Collapse sidebar
Watchlist
Screener
Filings
Earnings
Charts
Collapse sidebar
Screener
Stocks
Royalty Pharma
Business Segments
Products & Services
Unfunded Commitments
Unfunded Commitments
Royalty Pharma
·
Products & Services
·
3 segments
·
Rolls up to
Unfunded Commitments
Breakdown
Segments
JNJ‑4804
View metric
Litifilimab
View metric
TEV-408
View metric
Watchlist
Screener
Filings
Earnings
Charts
Quarterly
Annual
TTM
Segment
Q1 '26
Q2 '26
JNJ‑4804
$500M
$437.5M
Litifilimab
$25M
$0
Total
$600M
$502.65M
